SCHEMBL3926834

SCHEMBL3926834

CSc1nccc(N(C)c2cc(-c3ccccc3)c3ncn(Cc4ccccc4)c3c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.39
▸ HTR6 P50406 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ EGLN3 Q9H6Z9 1/20 0.35
▸ CYP11B1 P15538 3/20 0.34
▸ CYP11B2 P19099 3/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923592 0.85 DPP4 (0.37) ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1
SCHEMBL3933161 0.78 DPP4 (0.34) MEN1ALDH1A1POLBHPGDKMT2A
SCHEMBL5914072 0.75 SQOR (0.38) L3MBTL1CYP11B1CYP11B2
SCHEMBL5914335 0.72 IGF1R (0.41) KMT2AHTT
SCHEMBL5320096 0.72 BRD4 (0.37) MEN1ALDH1A1POLBHPGDKMT2A
SCHEMBL5260815 0.70 CSNK1E (0.39) LMNAMEN1ALDH1A1HPGDKMT2A
SCHEMBL4002611 0.69 KMT2A (0.37) LMNAMEN1ALDH1A1CYP1A2CYP2C9
SCHEMBL3922194 0.69 LMNA (0.56) LMNAMEN1ALDH1A1CYP1A2POLB
SCHEMBL3922575 0.68 LMNA (0.50) LMNAMEN1ALDH1A1CYP1A2POLB
SCHEMBL14395973 0.68 BRD4 (0.33) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041118-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2009-04-01 — — EP disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
US-20060247263-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247263-A1 Substituted heterocyclic compounds and methods of use MAPT, IAPP, MYLK2 LMNA 3794/4885HTR6 2824/4885MEN1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback